Glaxosmithkline
GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
DitchCarbon Score
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glaxosmithkline's reported carbon emissions
In 2024, GlaxoSmithKline (GSK) reported total carbon emissions of approximately 521,000,000 kg CO2e for Scope 1 and 44,000,000 kg CO2e for Scope 2 globally. In the UK, GSK's combined Scope 1 and 2 emissions were about 92,000,000 kg CO2e. The company has set ambitious climate targets, aiming for net zero emissions across all operations (Scope 1 and 2) by 2030 and across its full value chain (all scopes) by 2045. GSK has committed to reducing its absolute Scope 1 and 2 GHG emissions by 80% by 2030 from a 2020 baseline and by 90% by 2045. Additionally, the company aims to cut its Scope 3 emissions by 80% by 2030 and 90% by 2045, with a focus on areas such as purchased goods and services, business travel, and waste generated in operations. In 2021, GSK achieved a 15% reduction in Scope 1 and 2 emissions compared to 2020. The company is also a signatory of the Amazon Climate Pledge, reinforcing its commitment to sustainability. All emissions data and targets are sourced from GSK plc, with no cascaded data from parent organizations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
